Lineage acquired NeuroAIRMID, adding the clinical-stage HUNT-1 neural stem cell program for Huntington’s disease. Its 21-patient Phase 1B2A trial is enrolling, while $45.2 million in cash and marketable securities is expected to fund operations into the second quarter of 2028.
LCTX · Lineage Cell Therapeutics, Inc.
2 customers — 92% of revenue (the year ended December 31, 2025)
“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”
One customer — 92% of revenue (the year ended December 31, 2024)
“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 43%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Lineage acquired NeuroAirmid on November 12, 2026, adding the HUNT1 cell therapy for Huntington’s Disease. It paid $2.4 million in cash and issued 2.2 million common shares, with up to $48.0 million contingent on clinical development and regulatory milestones.
Lineage acquired NeuroAirmid on November 12, 2026, adding HUNT1, a Phase 1b/2a Huntington’s Disease cell therapy. Closing consideration included $2.4 million in cash, 2.2 million common shares, and up to $48.0 million in clinical and regulatory milestones.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Lineage reported Q2 net income of $1.5M driven by a non-cash $9.4M gain from warrant liability remeasurement as share price declined, while advancing wholly-owned pipeline assets COR1 into in vivo animal testing and ILT1 to multi-liter scale, and expanding the OpRegen GAlette study to 17 sites. Cash runway was extended one quarter to Q3 2028 at $50.8M.
- + Cash runway extended one quarter to Q3 2028 at $50.8M
- + COR1 program advanced into in vivo animal testing with initial preclinical data expected in 2026
- + ILT1 manufacturing initiative scaled from 0.5L to multi-liter scale
- + OpRegen GAlette study expanded from 6 to 17 clinical sites
- + Positive 3-year OpRegen Phase 1/2a data featuring sustained BCVA gains was showcased at Retinal Therapeutics Innovation Summit 2026
- − Total Q2 revenues declined $1.7M year-over-year to $1.1M due to lower Roche collaboration revenue and prior-year VAC termination
- − Q2 R&D expenses increased $1.7M year-over-year to $4.8M driven by preclinical programs
- − Diluted EPS was a loss of $0.03 despite reported basic net income of $0.01 per share, reflecting dilution from warrants
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| clinical award | $12M | third quarter 2026 | — |
| clinical sites | 17 | third quarter 2026 | — |
| Cohort 4 patients | 12 | third quarter 2026 | — |
| patients dosed with HUNT1 | 6 | third quarter 2026 | — |
| payment to NeuroAirmid investors | $4.7M | Upon closing of the transaction | — |
| translational funding | $16M | third quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LCTX
this stock
Lineage Cell Therapeutics, Inc.
|
$195.26M | -53.8% | +53.2% | — | 9.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 14
Lineage acquired NeuroAirmid on November 12, 2026, adding the HUNT1 cell therapy for Huntington’s Disease. It paid $2.4 million in cash and issued 2.2 million common shares, with up to $48.0 million contingent on clinical development and regulatory milestones.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LCTX | -15.6% | -22.8% | -36.2% | -22.8% | -53.8% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -7.0% | -13.6% | -27.0% | -14.1% | -54.9% |